Current Stanford Clinical Trials for Hodgkin’s Disease
Prospective randomized clinical trials for Hodgkin’s disease were initiated at Stanford University by Dr. Henry S. Kaplan and Dr. Saul A. Rosenberg in 1962. In the subsequent 25 years, nearly 1000 patients have been accrued to four generations of clinical trials. In addition, during the same period, a similar number of patients were treated with programs identical to those used on the clinical trials, but were not assigned by randomization (Table 1). Each generation of clinical trials has built strongly upon the experience obtained in the preceding trials and has also incorporated new concepts in Hodgkin’s disease management developed by other investigators. The use of standardized treatment programs among the nonrandomized patients and the careful follow-up of all patients permit evaluation of the entire cohort of nearly 2000 patients for identification of prognostic factors, longterm complications of therapy, etc.
KeywordsToxicity Leukemia Azine Oncol Methotrexate
Unable to display preview. Download preview PDF.
- Bonadonna G, Zucali R, Delena M, Valagussa P (1977) Combined chemotherapy ( MOPP or ABVD) - radiotherapy approach in advanced Hodgkin’s disease. Cancer Treat Rep 61: 769–777Google Scholar
- Hoppe RT, Horning SJ, Rosenberg SA (1985) The concept, evolution, and preliminary results of the current Stanford clinical trials for Hodgkin’s disease. Cancer Sury 4: 459–475Google Scholar
- Kaplan HS (1980) Hodgkin’s disease, 2nd edn. Harvard University Press (Cambridge, MA) Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease: 1962–1984. Int J Radiat Oncol Biol Phys 11: 5–22Google Scholar